Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

The evolution of clinical trials is being driven by an increased focus on patient perspectives and innovative statistical methodologies. Regulatory agencies are pushing for trials that better ...

The company’s launch is backed by an oversubscribed Series A round of $411m co-led by Forbion and General Atlantic. RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital ...

We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical trials and how the industry can navigate the ...

Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and infrastructure.